Actelion Pharmaceuticals Ltd

Type: Company
Name: Actelion Pharmaceuticals Ltd (Actelion Ltd)
Nationality: Switzerland
Web Address: http://www.actelion.com/
Fact Sheet: Fact Sheet for Actelion Ltd
First reported 12 mins ago - Updated 12 mins ago - 1 reports

Oral Ponesimod Relieves Chronic Plaque Psoriasis

NEW YORK (Reuters Health) - Ponesimod (Actelion Pharmaceuticals), an oral selective modulator of the sphingosine 1-phosphate receptor, yielded significant clinical benefit in a phase 2 trial of patients with moderate to severe chronic plaque psoriasis, ... [Published General Medicine eJournal - 12 mins ago]
First reported Aug 21 2014 - Updated Aug 21 2014 - 4 reports

Research and Markets: Global Lysosomal Storage Diseases Market 2014-2018: Key Vendors are Actelion Pharmaceuticals, …

DUBLIN--(BUSINESS WIRE)--Research and Markets ( http://www.researchandmarkets.com/research/5f7fvn/global_lysosomal ) has announced the addition of the "Global Lysosomal Storage Diseases Market 2014-2018" report to their offering.The Global Lysosomal ... [Published Yahoo! Finance - Aug 21 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

Cardiac Arrhythmias and Defects in Systemic Sclerosis

Authors and DisclosuresAlessandra Vacca 1 , Christophe Meune 2 , Jessica Gordon 3 , Lorinda Chung 4,5 , Susanna Proudman 6 , Shervin Assassi 7 , Mandana Nikpour 8 , Tatiana S. Rodriguez-Reyna 9 , Dinesh Khanna 10 , Robert Lafyatis 11 , Marco Matucci-Cerinic ... [Published Theheart.org - Aug 20 2014]
First reported Aug 18 2014 - Updated Aug 19 2014 - 1 reports

Achillion Pharmaceuticals Soars on Mid-Stage HCV Study Data - Analyst Blog

Achillion Pharmaceuticals, Inc. ( ACHN ) reported positive interim results from a phase II study (n=12) on its hepatitis C virus (HCV) candidate, ACH-3102. The company’s shares jumped 9.6% following the news.The mid-stage study is evaluating a ribavirin-free ... [Published Zacks.com - Aug 18 2014]
First reported Aug 18 2014 - Updated Aug 19 2014 - 2 reports

NewLink Genetics Corp. (NLNK) Jumps: Stock Adds 8.6% in Session

NewLink Genetics Corporation ( NLNK ) was a big mover last session, as its shares rose almost 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the company, ... [Published Yahoo! Finance - Aug 18 2014]
First reported Aug 18 2014 - Updated Aug 19 2014 - 1 reports

Achillion Pharmaceuticals (ACHN) in Focus: Stock Up 9.6%

Achillion Pharmaceuticals ( ACHN ) was a big mover last session, as the company saw its shares gain nearly 10% on the day. This rally higher can be attributable to solid volume with far more shares changing hands than in a normal session. This continues ... [Published Yahoo! Finance - Aug 18 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

Zurich Stocks Mostly Higher; Swisscom Down -- Market Talk

1609 GMT Switzerland's SMI stocks index rises 1.04% to 8453.59. Roche jumps 1.27% even after Japan's Chugai denies it's in buyout talks with the Swiss pharmaceutical giant. Fellow drug giant Novartis rises 1.60%, while Actelion, Europe's biggest biotech, ... [Published 4 Traders - Aug 18 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 2 reports

Global Lysosomal Storage Diseases Market 2014-2018: Key Vendors are Actelion, BioMarin, Genzyme and Shire

These deficiencies result in deficient enzymatic activity which, in turn, leads to accumulation of partially digested or undigested macromolecules inside the cell. The clinical manifestations of lysosomal storage diseases depend on the type of substrate ... [Published Indianapolis Business Journal - Aug 18 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

Place a Bet on Potential Takeover Target InterMune

Popular Posts: Recent Posts: InterMune ( ITMN ) — This biotech company specializes in therapies for pulmonology and orphan fibrotic diseases. It produces the drug pirfenidone, under the trade name Esbriet, for the treatment of idiopathic pulmonary fibrosis ... [Published InvestorPlace.com - Aug 18 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

Employers like "skinny" health plans

GlaxoSmithKline, Actelion, Sanofi and Roche are said to be among a host of suitors.The regulator and patients will chat for two days in October.A study indicates consumers stop using them at the six-month mark. ... [Published Medical Marketing And Media - Aug 15 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

Global Lysosomal Storage Diseases Market 2014-2018: Key Vendors are Actelion, BioMarin, Genzyme and Shire

Dublin, Aug. 15, 2014 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/qslj8l/global_lysosomal) has announced the addition of the "Global Lysosomal Storage Diseases Market 2014-2018" report to their offering.The term ... [Published GlobeNewswire - Aug 15 2014]
First reported Aug 05 2014 - Updated Aug 06 2014 - 7 reports

Actelion partners with PatientsLikeMe on blood cancer research tool

Will create patient-reported outcomes tool for rare form of non-Hodgkin’s lymphoma ... [Published PMLive - Aug 06 2014]

Quotes

Drs. Ryan and Menter conclude, "New, safe, cost-effective oral therapies are needed to treat all forms of psoriasis. Ponesimod fits this profile as an innovative new molecule, which adds to the growing array of therapies. Further adequately powered, robust, long-term studies are essential to assess long-term efficacy and safety fully, particularly the cardiovascular safety of ponesimod, in patients with psoriasis and all associated comorbidities."
"These positive results are very encouraging, particularly because both patients and physicians saw a statistically significant improvement in the appearance of cellulite after CCH treatment" commented Thomas L Wegman
...a statistically significant improvement in the appearance of cellulite after CCH treatment," commented Thomas L Wegman , President of BioSpecifics. "The market for cellulite treatment is large, which makes these data very exciting for the prospective commercial success of CCH in this indication. The results also position CCH as a potential treatment for other aesthetic needs, so we are eager to see continued progress by Auxilium in initiating a subsequent Phase 2b trial of CCH in cellulite in the second quarter of 2015."
"Our goal is to price this in a way that does not bias the medical decision-making process" Meeker said

More Content

All (281) | News (247) | Reports (0) | Blogs (30) | Audio/Video (0) | Fact Sheets (2) | Press Releases (1)
sort by: Date | Relevance
Oral Ponesimod Relieves Chronic Plaque Psoriasis [Published General Medicine eJournal - 12 mins ago]
BioSpecifics Technologies Corp. Announces Posit... [Published TheStreet.com - 23 hours ago]
BioSpecifics Technologies Corp. Announces Posit... [Published Stock Nod - 23 hours ago]
BioSpecifics Technologies Corp. Announces Posit... [Published Reliance Trust - 23 hours ago]
FDA gives green light to Genzyme’s oral Gaucher... [Published PMLive - Aug 21 2014]
Research and Markets: Global Lysosomal Storage ... [Published Yahoo! Finance - Aug 21 2014]
Research and Markets: Global Lysosomal Storage ... [Published Fort Mills Times - Aug 21 2014]
Research and Markets: Global Lysosomal Storage ... [Published Business Wire Health News - Aug 21 2014]
Global Lysosomal Storage Diseases Market 2014-2... [Published Individual.com - Aug 21 2014]
Price could be key for Sanofi's new Gaucher pil... [Published FiercePharma - Aug 20 2014]
Cardiac Arrhythmias and Defects in Systemic Scl... [Published Theheart.org - Aug 20 2014]
US nod for Genzyme's Gaucher pills [Published Pharma Times - Aug 20 2014]
Sanoif Wins U.S. Approval for New Gaucher Disea... [Published Bloomberg - Aug 19 2014]
FDA okays Genzyme pill for Gaucher disease [Published Boston Globe - Aug 19 2014]
Achillion Pharmaceuticals Soars on Mid-Stage HC... [Published Zacks.com - Aug 18 2014]
Doctors do not care about your Fitbit [Published Medical Marketing And Media - Aug 18 2014]
Eisai sues FDA for more patent life [Published Medical Marketing And Media - Aug 18 2014]
Roche has no rights to Sovaldi, panel rules [Published Medical Marketing And Media - Aug 18 2014]
Ligand Up on Multi-Program Captisol Deal with A... [Published Zacks.com - Aug 18 2014]
Achillion Pharmaceuticals Soars on Mid-Stage HC... [Published Yahoo! Finance - Aug 18 2014]
Gilead Scores Legal Victory Over Roche for Sova... [Published Zacks.com - Aug 18 2014]
Gilead Scores Legal Victory Over Roche for Sova... [Published Yahoo! Finance - Aug 18 2014]
Zurich Stocks Mostly Higher; Swisscom Down -- M... [Published 4 Traders - Aug 18 2014]
Global Lysosomal Storage Diseases Market 2014-2... [Published Indianapolis Business Journal - Aug 18 2014]
Global Lysosomal Storage Diseases Market 2014-2... [Published PR Newswire: General Business - Aug 18 2014]
NewLink Genetics Corp. (NLNK) Jumps: Stock Adds... [Published Yahoo! Finance - Aug 18 2014]
Epizyme (EPZM) Crumbles: Stock Falls by 5.9% [Published Yahoo! Finance - Aug 18 2014]
Achillion Pharmaceuticals (ACHN) in Focus: Stoc... [Published Yahoo! Finance - Aug 18 2014]
Place a Bet on Potential Takeover Target InterMune [Published InvestorPlace.com - Aug 18 2014]
Sclerosis: Autologous Cell Transfers May Help P... [Published General Medicine eJournal - Aug 18 2014]
1 2 3 4 5 6 7 8 9 10
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Research and Markets: Global Lysosomal Storage ... [Published Business Wire Health News - Aug 21 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5f7fvn/global_lysosomal) has announced the addition of the "Global Lysosomal Storage Diseases Market 2014-2018" report to their offering. The Global Lysosomal Storage ...
Global Lysosomal Storage Diseases Market 2014-2... [Published PR Newswire: General Business - Aug 18 2014]
DUBLIN, Aug. 18, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Lysosomal Storage Diseases Market 2014-2018" report to their offering. The term lysosomal storage diseases refers to a group of rare inherited disorders ...
Stop Abusing the Loophole! [Published The Big Red Biotech Blog - Aug 07 2014]
The US Treasury and lawmakers say they will push ahead with their attempts to prevent further tax inversion deals from proceeding --- and they will push to make this legislation retroactive to take away rewards accomplished deals may have already gleaned. ...
PatientsLikeMe and Actelion to Develop New Pati... [Published Business Wire Health News - Aug 05 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--PatientsLikeMe and Actelion Ltd. are partnering in a research initiative to create a new patient-reported outcomes tool for the rare form of non-Hodgkin's lymphoma called MF-CTCL. ...
[Department of Error] Department of Error [Published The Lancet - Jul 25 2014]
Devos P, Haeffner-Cavaillon N, Ledoux S, Balandier C, Ménard J. Assessing the French Alzheimer plan. Lancet 2014; 383: 1805—In this Correspondence (May 24), the declaration of interests should have read: “JM was involved in the design of the plan. JM ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
PatientsLikeMe and Actelion to Develop New Pati... [Published PatientsLikeMe Press Release - Aug 05 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.